Epizootic hemorrhagic disease vaccine
AssigneesKansas State University Research Foundation, The United States of America as represented by the Secretary of Agriculture
InventorsJuergen A. Richt, Igor Morozov, Sun Young Sunwoo, William C. Wilson
Life of this patent
Estimating the term…
Abstract
The present disclosure provides for an immunogenic composition against epizootic hemorrhagic disease virus (EHDV). The immunogenic composition has been shown to be efficacious in inducing serum neutralizing antibodies against EHDV and intended to be used to prevent or reduce clinical symptoms associated with EHDV infection in susceptible animals. The disclosure provides for composition and methods that represent an improvement over previous strategies for treating and preventing EHDV.
Claims37
An immunogenic composition comprising:
- a combination selected from the group consisting of at least one VP2 subunit and at least one VP5 subunit from EHDV, at least two VP2 subunits from different serotypes of EHDV, and at least 2 different VP5 subunits from different serotypes of EHDV;
- and
- at least one component selected from the group consisting of antigens, pharmaceutical carriers, adjuvants, preservatives, stabilizers, or combinations thereof.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of reducing the incidence or severity of at least one clinical symptom of EHD, comprising the step of administering an immunogenic composition comprising a VP2 subunit and a VP5 subunit from EHDV and at least one component selected from the group consisting of antigens, pharmaceutical carriers, adjuvants, preservatives, stabilizers, or combinations thereof.
(canceled)
(canceled)
(canceled)
A method of reducing the incidence or severity of at least one clinical symptom associated with subclinical EHD, comprising the step of administering an immunogenic composition comprising a VP2 subunit and a VP5 subunit from EHDV and at least one component selected from the group consisting of antigens, pharmaceutical carriers, adjuvants, preservatives, stabilizers, or combinations thereof.
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.